- Marketwired•10 days ago
Accurexa, Inc. , a small-cap biotech focused on chemotherapy and immunology, is an up-and-coming leader in the neurological therapy space. Currently, Accurexa is working on the targeted delivery of such ...
- Zacks Small Cap Research•10 days ago
As of September 30, 2016, DelMar held $4.8 million in cash. In May 2016, DelMar (DMPI) announced a closing of a private placement of Preferred Shares for gross proceeds of $6.1 million, and the restructuring of 2,095,238 warrants. DelMar has made a great deal of progress in the development of its lead product candidate, VAL-083. These new funds will allow the company to maintain the momentum it has established in this program through 2017.
- PR Newswire•17 days agoDelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting
VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 21, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today summarized the Company's presentations at the CNS Anticancer Drug Discovery and Development Conference and Society for NeuroOncology Annual meeting, which was held November 16-20, 2016 in Scottsdale, Arizona. "It was an honor to be invited to share and discuss our research with leaders in the global neuro-oncology community," stated Mr. Bacha.
DMPI : Summary for DelMar Pharmaceuticals, Inc. - Yahoo Finance
Del Mar Pharmaceuticals Inc. (DMPI)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.01 x 100|
|Ask||3.85 x 200|
|Day's Range||3.80 - 3.85|
|52 Week Range||0.75 - 10.87|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-7.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|